Estimation of Plasma Glucose and Creatinine Level in Alloxan-induced Diabetic Wistar Rats treated with Metformin and Thiazolidinediones

Year 2018, Volume: 4 Issue: 2, 73 - 77, 01.04.2018

Ojo Patience Oluwatomilayo Akinola Busayo Oluwole

https://doi.org/10.5455/umj.20180116075446

Abstract

Introduction: Diabetes increases the risk of developing neuropathy. In this study, we estimate the effect of Metformin, rosiglitazone, and pioglitazone on the body weight, blood glucose and creatinine level of alloxan-induced diabetic rats. Materials and Method: Alloxan 150 mg/kg was used to induce hyperglycemia in fasted rats. Hyperglycaemia was treated with metformin, 150 mg/kg/d; pioglitazone, 3 mg/kg/d; and rosiglitazone, 10 mg/kg/d . The anti-diabetic drugs were administered orally for 28 days. The kidneys were removed when the animals were sacrificed plasma and kidney creatinine level was measured. Results: There was the reduction in weight of diabetic rats and those administered with metformin while there was an increase in weight of rats administered with rosiglitazone and pioglitazone. There is also reduction in blood glucose level of all treated rats compared with the diabetes control. The effects of creatinine on muscle metabolism generation and serum are insignificant at P≤0.05. Conclusion: This experiment suggests that short-term diabetes does not have an effect on plasma creatinine level and muscle metabolism of alloxan-induced diabetic rats.

Keywords

Plasma glucose, Creatinine, Metformin, Thiazolidinediones

References

• 1.Aguiree, Florencia, Brown, Alex, Cho, Nam Ho, Dahlquist, Gisela, Dodd, Sheree, Dunning, Trisha, Hirst, Michael, Hwang, Christopher, Magliano, Dianna, Patterson, Chris, Scott Courtney, Shaw, Jonathon, Soltesz, Gyula, Usher-Smith, Juliet and Whiting, David, IDF Diabetes Atlas : sixth edition, 6th ed.
• 2013. Accessed December 22, 2017, from http://dro.deakin. edu.au/view/DU:30060687
• 2.Rodica P., Laurel R, Subramaniam P, Mathias K, Frank CB and Eva L.F. The Management of Diabetic Neuropathyin CKD and Dialysis patients. Am J Kidney Dis.2010; pp. 365-368.
• 3. Yue TL, Bao W, Gu JL, Cui J, Tao L, et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischaemia/reperfusion-induced myocardial injury. Diabetes 2005; 55: 554-62.
• 4. Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008; 23 (9): 2750-60.
• 5.Majithiya JB, Balaraman R. Metformin reduces blood pressure and restores endothelial functions in aorta os streptozotocininduced diabetic rats. Life Sci 2006; 78 (22): 2615-24
• 6.Crocker H., Shephard M. D., and White, G. H. Evaluation of an enzymatic method for determining creatinine in plasma. Journal of clinical pathology 1988; 41(5): 576-581
• 7.Wei and Willams. Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats. J Pharmacol Exp Ther. 2012; 341(3): 617–625.
• 8.Mohamed Z., Noha A., Mansour H. and Lobna F. Pioglitazone Versus Metformin In Two Rat Models Of Glucose Intolerance And Diabetes. Pak. J. Pharm. Sci. 2010; 23(3): 305-312
• 9. Semenkovich CF. TZDs and diabetes: testing the waters. Nat Med 2005; 11:822–824
• 10. Pouya Pournaghi, Rajab-Ali Sadrkhanlou, Shapour Hasanzadeh, and Azadeh Foroughi. An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats. Vet Res Forum. Spring 2012; 3(2): 79–84.